Krilogy Financial LLC Cuts Stock Position in STERIS plc $STE

Krilogy Financial LLC lessened its holdings in shares of STERIS plc (NYSE:STE) by 65.7% during the 1st quarter, Holdings Channel reports. The firm owned 1,752 shares of the medical equipment provider’s stock after selling 3,350 shares during the period. Krilogy Financial LLC’s holdings in STERIS were worth $385,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Board of the Pension Protection Fund acquired a new stake in STERIS during the 4th quarter worth approximately $25,000. Harbor Investment Advisory LLC grew its stake in shares of STERIS by 115.4% in the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 60 shares in the last quarter. Activest Wealth Management increased its position in shares of STERIS by 423.8% during the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 89 shares during the period. Measured Wealth Private Client Group LLC acquired a new stake in shares of STERIS in the fourth quarter valued at $28,000. Finally, Geneos Wealth Management Inc. raised its stake in shares of STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Buying and Selling at STERIS

In other STERIS news, CEO Daniel A. Carestio sold 1,374 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $212.00, for a total value of $291,288.00. Following the completion of the sale, the chief executive officer owned 63,647 shares in the company, valued at approximately $13,493,164. The trade was a 2.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP John Adam Zangerle sold 1,419 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the sale, the vice president owned 35,259 shares of the company’s stock, valued at approximately $7,379,003.52. This represents a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 7,328 shares of company stock worth $1,554,051. 1.12% of the stock is owned by insiders.

STERIS Stock Performance

Shares of STERIS stock opened at $215.59 on Monday. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44. The firm’s 50 day moving average is $212.77 and its two-hundred day moving average is $233.10. The firm has a market capitalization of $21.01 billion, a P/E ratio of 27.19 and a beta of 0.93.

STERIS (NYSE:STE) last issued its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.59 billion. STERIS had a net margin of 13.18% and a return on equity of 14.15%. The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Research analysts forecast that STERIS plc will post 11.18 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 26th. Stockholders of record on Monday, June 8th were given a dividend of $0.63 per share. The ex-dividend date was Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. STERIS’s payout ratio is 31.78%.

Wall Street Analysts Forecast Growth

STE has been the subject of several analyst reports. Piper Sandler reissued an “overweight” rating and set a $270.00 target price on shares of STERIS in a research note on Thursday, May 21st. Wall Street Zen cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Weiss Ratings cut STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Finally, KeyCorp lowered their price objective on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $278.00.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.